Research tool page — not in the public editorial index
This company can still be explored inside Wall Street Score, but this URL remains noindex and is not eligible for Google-served ads until source-specific publisher curation is documented and the public research-quality checks pass.
Haleon plc
HLN · Price history
Price at last available close
$8.77
−$0.23 (-2.61%) 1M
2026-10-30
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Haleon plc
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements.
How they make money
Haleon is a global consumer healthcare company that generates revenue by developing, manufacturing, and marketing a portfolio of over-the-counter medicines, vitamins, minerals, and oral health products. The company leverages deep human understanding and scientific expertise to sell these products directly to consumers through retail channels, pharmacies, and e-commerce platforms, supported by recommendations from health professionals.
Products & services
Consumer healthcare products including oral health (Sensodyne, parodontax), pain relief (Advil, Voltaren), respiratory health, digestive health, and vitamins, minerals, and supplements (VMS).
Brands & revenue mix
Leading oral health brand focused on sensitivity.
Separate brand revenue is not available in this research.Source
Oral health brand focused on gum health.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract manufacturing and raw material suppliers — The company utilizes a network of third-party suppliers for raw materials and contract manufacturing services; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Europanel — A joint venture between Numerator UK Ltd and YouGov GMBh that conducts reach modelling studies for the company.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
43
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
72
Strong
Financial Strength
76
Business Quality / Moat
47
Management
91
Growth Quality
77
Risk / Durability
81
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
37
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
44/100
Building Historical Record
Model Score 44/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for HLN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can HLN maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is HLN's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is HLN's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify HLN's current valuation?
Essential Investment Snapshot
Wall Street Score
43
Opportunity Score
37
Market Cap
$38.58B
P/E Ratio
10.8
EPS
$0.83
52-Week High
$11.28
52-Week Low
$8.65
Beta
0.24
Intrinsic Value
$7.97
Analyst Target
$10.20
Shares Outstanding
4.51B
Total Revenue
$25.71B
Total Debt
$10.88B
Dividend
No current dividend
Liquidation Value / Share
$4.81
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for HLN
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on HLN.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Strong portfolio of trusted, science-based consumer healthcare brands.
- +Deep relationships with health professionals and pharmacy networks.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - Specialty & Generic industry.
- −Supply chain disruptions and manufacturing constraints.
- −Regulatory changes and compliance requirements in global markets.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
43
Sep 28, 2026
Change
+0.1
points
Current Score
43
Oct 1, 2026
Category Changes
HLN increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
41
Projected Change
-2.2 points
Preliminary comparable-period financial changes suggest decline of approximately 2.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$8.77
Model Intrinsic Value
$7.97
Difference
+$0.80
+10.0% vs IV
Margin of Safety
-10.0%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.71B | $14.63B | $14.90B | $14.99B | ···· | ···· | ···· | ···· |
| Cost of Revenue | $8.97B | $5.08B | $5.68B | $5.76B | ···· | ···· | ···· | ···· |
| Gross Profit | $16.74B | $9.27B | $9.22B | $9.23B | ···· | ···· | ···· | ···· |
| Research & Development | $715.8M | $408.7M | $395.3M | $412.6M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $10.16B | $5.79B | $5.75B | $5.69B | ···· | ···· | ···· | ···· |
| Operating Expenses | $10.90B | $5.88B | $6.29B | $6.59B | ···· | ···· | ···· | ···· |
| EBITDA | $6.64B | $3.82B | $3.34B | $3.12B | ···· | ···· | ···· | ···· |
| Operating Income | $5.84B | $3.20B | $2.93B | $2.65B | ···· | ···· | ···· | ···· |
| Interest Expense | $677.4M | $441.2M | $522.7M | $549.2M | ···· | ···· | ···· | ···· |
| Income Before Tax | $4.97B | $2.85B | $2.53B | $2.16B | ···· | ···· | ···· | ···· |
| Income Tax Expense | $1.18B | $612.4M | $577.1M | $685.9M | ···· | ···· | ···· | ···· |
| Net Income | $3.76B | $2.16B | $1.91B | $1.39B | ···· | ···· | ···· | ···· |
| Basic EPS | $0.83 | $0.48 | $0.42 | $0.32 | ···· | ···· | ···· | ···· |
| Basic Shares | 4.44B | 4.48B | 4.57B | 4.63B | ···· | ···· | ···· | ···· |
| Diluted Shares | 4.46B | 4.51B | 4.59B | 4.63B | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$7.49B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.23
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-3.0%
Cash Change
+21.5%
Margin Change
-1.1 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
What Weakened
- Margins contracted
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels. Pressure indicators included EPS growth, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 3.0%. EPS declined 5.6%. Cash increased 21.5%. Total debt declined 3.0%. Net income margin declined by 1.1 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
7
Smart Money
7
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - Specialty & GenericNews
ASAIY or HLN: Which Is the Better Value Stock Right Now?
LCUT vs. HLN: Which Stock Is the Better Value Option?
Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
LCUT or HLN: Which Is the Better Value Stock Right Now?
Rumor Mill · HLN
Corporate developments & opportunities
No reviewed developments match this filter.
The reliability percentage measures the strength of the supporting evidence—not the probability that the event will occur or that the stock will rise. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial